NICE recommends rivaroxaban for stroke prevention in AF

Rivaroxaban (Xarelto) has been approved by NICE for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).

Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
Xarelto (rivaroxaban) is taken orally once daily with food and does not require regular anticoagulation monitoring
The anticoagulant can be used in patients with non-valvular AF with one or more of the following risk factors:
•    Previous stroke or transient ischaemic attack
•    Congestive heart failure
•    Age 75 years or older
•    Diabetes
•    Hypertension.

Rivaroxaban is also recommended by NICE at a lower dose for the prevention of venous thromboembolism following elective total hip or knee replacement surgery.            

Further details
NICE guidance on rivaroxaban in atrial fibrillation

Further information:
View Xarelto drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more